Zivo Bioscience, Inc. (ZIVO) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US98978N2009

Price
8.59 USD
Market cap
27.21 m USD
P/E (2025)
–
P/S (2025)
228.57
Dividend yield
0.00 %
Net margin
-8,311.12 %
Return on equity (ROE)
263.93 %
Return on assets (ROA)
-1,490.71 %

Zivo Bioscience, Inc. financials

Fiscal year20242025
Revenue157,220.00 USD119,025.00 USD
Gross profit48,952.00 USD39,934.00 USD
Operating income-13.36 m USD-9.85 m USD
EBIT-13.38 m USD–
Net income-13.38 m USD-9.89 m USD
Diluted EPS – continuing operations-4.23 USD–

Full history since 2000, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Zivo Bioscience, Inc.

ZIVO Bioscience, Inc., together with its subsidiaries, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. It offers poultry gut health, avian influenza, bovine mastitis, canine joint health, human immune modification, human functional food ingredients, algal biomass for human food, and biomass for supporting skin health and anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Troy, Michigan.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.